Peak Group: Subsidiary voluntarily withdraws drug registration clinical trial application.

Peak Group Announcement: The company's wholly-owned subsidiary Peak Pharmaceuticals has received a "Notice of Termination of Drug Registration Application" issued by the National Medical Products Administration for "C2235 and C2235 tablets". This is because Peak Pharmaceuticals voluntarily withdrew the application, and the company plans to resubmit the drug registration clinical trial application after completing related research. The withdrawal of the "C2235 and C2235 tablets" drug registration clinical trial application by Peak Pharmaceuticals this time will not have a significant impact on the company's current performance.